Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 991

1.

Common and unique therapeutic mechanisms of stimulant and nonstimulant treatments for attention-deficit/hyperactivity disorder.

Schulz KP, Fan J, Bédard AC, Clerkin SM, Ivanov I, Tang CY, Halperin JM, Newcorn JH.

Arch Gen Psychiatry. 2012 Sep;69(9):952-61. doi: 10.1001/archgenpsychiatry.2011.2053.

PMID:
22945622
2.

Shared and drug-specific effects of atomoxetine and methylphenidate on inhibitory brain dysfunction in medication-naive ADHD boys.

Cubillo A, Smith AB, Barrett N, Giampietro V, Brammer MJ, Simmons A, Rubia K.

Cereb Cortex. 2014 Jan;24(1):174-85. doi: 10.1093/cercor/bhs296. Epub 2012 Oct 9.

3.

Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.

Quintana H, Cherlin EA, Duesenberg DA, Bangs ME, Ramsey JL, Feldman PD, Allen AJ, Kelsey DK.

Clin Ther. 2007 Jun;29(6):1168-77.

PMID:
17692731
4.

Differential therapeutic effects of 12-week treatment of atomoxetine and methylphenidate on drug-naïve children with attention deficit/hyperactivity disorder: A counting Stroop functional MRI study.

Chou TL, Chia S, Shang CY, Gau SS.

Eur Neuropsychopharmacol. 2015 Dec;25(12):2300-10. doi: 10.1016/j.euroneuro.2015.08.024. Epub 2015 Sep 8.

PMID:
26409297
5.

Neurofunctional effects of methylphenidate and atomoxetine in boys with attention-deficit/hyperactivity disorder during time discrimination.

Smith A, Cubillo A, Barrett N, Giampietro V, Simmons A, Brammer M, Rubia K.

Biol Psychiatry. 2013 Oct 15;74(8):615-22. doi: 10.1016/j.biopsych.2013.03.030. Epub 2013 May 31.

PMID:
23731741
6.

Functional magnetic resonance imaging of methylphenidate and placebo in attention-deficit/hyperactivity disorder during the multi-source interference task.

Bush G, Spencer TJ, Holmes J, Shin LM, Valera EM, Seidman LJ, Makris N, Surman C, Aleardi M, Mick E, Biederman J.

Arch Gen Psychiatry. 2008 Jan;65(1):102-14. doi: 10.1001/archgenpsychiatry.2007.16.

PMID:
18180434
7.

Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial.

Wang Y, Zheng Y, Du Y, Song DH, Shin YJ, Cho SC, Kim BN, Ahn DH, Marquez-Caraveo ME, Gao H, Williams DW, Levine LR.

Aust N Z J Psychiatry. 2007 Mar;41(3):222-30.

PMID:
17464703
8.

Methylphenidate vs atomoxetine: personalized medicine in attention- deficit/hyperactivity disorder.

Heinrich H, Studer P, Moll GH, Kratz O.

JAMA Psychiatry. 2013 May;70(5):545. doi: 10.1001/jamapsychiatry.2013.760. No abstract available.

PMID:
23636880
9.

Transitioning to OROS(®) methylphenidate from atomoxetine is effective in children and adolescents with ADHD.

Niederkirchner K, Slawik L, Wermelskirchen D, Rettig K, Schäuble B.

Expert Rev Neurother. 2011 Apr;11(4):499-508. doi: 10.1586/ern.11.18.

PMID:
21469923
10.
11.

Drug-specific laterality effects on frontal lobe activation of atomoxetine and methylphenidate in attention deficit hyperactivity disorder boys during working memory.

Cubillo A, Smith AB, Barrett N, Giampietro V, Brammer M, Simmons A, Rubia K.

Psychol Med. 2014 Feb;44(3):633-46. doi: 10.1017/S0033291713000676. Epub 2013 Apr 19.

PMID:
23597077
12.

Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder.

Gibson AP, Bettinger TL, Patel NC, Crismon ML.

Ann Pharmacother. 2006 Jun;40(6):1134-42. Epub 2006 May 30. Review.

PMID:
16735655
13.

Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.

Garnock-Jones KP, Keating GM.

Paediatr Drugs. 2009;11(3):203-26. doi: 10.2165/00148581-200911030-00005. Review.

PMID:
19445548
14.

Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder.

Weisler RH, Pandina GJ, Daly EJ, Cooper K, Gassmann-Mayer C; 31001074-ATT2001 Study Investigators.

CNS Drugs. 2012 May 1;26(5):421-34. doi: 10.2165/11631990-000000000-00000.

PMID:
22519922
15.

A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes.

Faraone SV, Glatt SJ.

J Clin Psychiatry. 2010 Jun;71(6):754-63. doi: 10.4088/JCP.08m04902pur. Epub 2009 Dec 29.

PMID:
20051220
16.

Comparison of the inhibitory and excitatory effects of ADHD medications methylphenidate and atomoxetine on motor cortex.

Gilbert DL, Ridel KR, Sallee FR, Zhang J, Lipps TD, Wassermann EM.

Neuropsychopharmacology. 2006 Feb;31(2):442-9.

17.

Core ADHD symptom improvement with atomoxetine versus methylphenidate: a direct comparison meta-analysis.

Hazell PL, Kohn MR, Dickson R, Walton RJ, Granger RE, Wyk GW.

J Atten Disord. 2011 Nov;15(8):674-83. doi: 10.1177/1087054710379737. Epub 2010 Sep 13.

PMID:
20837981
18.

A head-to-head randomized clinical trial of methylphenidate and atomoxetine treatment for executive function in adults with attention-deficit hyperactivity disorder.

Ni HC, Shang CY, Gau SS, Lin YJ, Huang HC, Yang LK.

Int J Neuropsychopharmacol. 2013 Oct;16(9):1959-73. doi: 10.1017/S1461145713000357. Epub 2013 May 14.

PMID:
23672818
19.

Attention-deficit-hyperactivity disorder: an update.

Dopheide JA, Pliszka SR.

Pharmacotherapy. 2009 Jun;29(6):656-79. doi: 10.1592/phco.29.6.656. Review.

PMID:
19476419
20.

Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial.

Kratochvil CJ, Heiligenstein JH, Dittmann R, Spencer TJ, Biederman J, Wernicke J, Newcorn JH, Casat C, Milton D, Michelson D.

J Am Acad Child Adolesc Psychiatry. 2002 Jul;41(7):776-84.

PMID:
12108801

Supplemental Content

Support Center